AbbVie's Allergan Aesthetics has secured European approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neurotoxin indicated for glabellar frown lines. Boey's differentiation lies in onset speed and duration profile—a distinct clinical positioning versus Botox (onset 3–7 days, duration 12+ weeks) and Dysport (faster onset, variable duration).
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neurotoxin Reshapes Toxin Economics
Boey (trenibotulinumtoxinE) becomes the first rapid-onset, short-duration neuromodulator approved in Europe, fragmenting the toxin market.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Boey's rapid-onset, short-duration profile fragments the toxin market and signals AbbVie's defense against Revance and Evolus.
For US medspa owners, Boey's EU approval signals AbbVie's intent to fragment the toxin market and defend share against Revance's Daxxify (long-acting) and Evolus's Jeuveau (aggressive rebate pricing). A rapid-onset, short-duration product appeals to patients seeking trial treatments or frequent touch-ups, creating new per-unit volume opportunities—but also cannibalization risk within a practice's existing Botox/Dysport patient base. Watch for US FDA filing; if approved, expect aggressive Alle rebates and MSO bundling to drive adoption.
Source: original report ↗
Frequently asked questions
What is Boey and how is it different from Botox?
Boey (trenibotulinumtoxinE) is a rapid-onset, short-duration neurotoxin approved in Europe for glabellar frown lines. Unlike Botox, which takes 3–7 days to work and lasts 12+ weeks, Boey offers faster onset and shorter duration, making it ideal for patients wanting trial treatments or frequent touch-ups.
When will Boey be available in the US?
Boey has EU approval but has not yet been approved by the US FDA. AbbVie is expected to file for US FDA approval; watch for announcements on the timeline. If approved, expect aggressive rebates and MSO bundling strategies to drive adoption.
How will Boey affect my medspa's toxin revenue?
Boey creates new per-unit volume opportunities by attracting patients seeking trial treatments or frequent touch-ups, but poses cannibalization risk if existing Botox/Dysport patients switch. The short duration may increase appointment frequency but could reduce per-patient revenue if pricing is competitive.
Why is Boey's short duration a selling point?
Patients hesitant about longer-lasting results can use Boey to trial neurotoxin treatments with lower commitment. The shorter duration also appeals to those who want more frequent adjustments or prefer reversibility, creating a distinct market segment from traditional long-acting options.
How does Boey fit into the competitive toxin landscape?
Boey positions AbbVie against Revance's Daxxify (long-acting) and Evolus's Jeuveau (price-aggressive), fragmenting the market by onset and duration. This diversification allows AbbVie to capture patients across the preference spectrum—from those wanting quick results to those seeking extended duration.
Should I stock Boey when it launches in the US?
Adoption strategy depends on your patient mix and competitive positioning. If you have demand for trial treatments or frequent-touch-up patients, Boey offers differentiation. Monitor early adoption data and AbbVie's rebate structure before committing inventory, as pricing and bundling will drive ROI.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.